Exploring protein kinase inhibitors: potentiating gemcitabine efficacy in pancreatic cancer

Pancreas. 2012 Apr;41(3):496-8. doi: 10.1097/MPA.0b013e318230f71a.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antimetabolites, Antineoplastic / pharmacology
  • Antineoplastic Combined Chemotherapy Protocols / pharmacology*
  • Carcinoma, Pancreatic Ductal / enzymology*
  • Carcinoma, Pancreatic Ductal / pathology
  • Cell Line, Tumor
  • Cell Survival / drug effects
  • Deoxycytidine / analogs & derivatives
  • Deoxycytidine / pharmacology
  • Dose-Response Relationship, Drug
  • Drug Resistance, Neoplasm
  • Drug Synergism
  • Gemcitabine
  • Humans
  • Inhibitory Concentration 50
  • Molecular Targeted Therapy*
  • Pancreatic Neoplasms / enzymology*
  • Pancreatic Neoplasms / pathology
  • Protein Kinase Inhibitors / pharmacology

Substances

  • Antimetabolites, Antineoplastic
  • Protein Kinase Inhibitors
  • Deoxycytidine
  • Gemcitabine